Member Info for LlamaFarmer

Basic salary

The basic salary for each Director is determined by considering the performance of the individual and

information, where available, on the rates of salary for similar posts in comparable businesses. The Chief

Executive Officer’s current salary is £165,500 (2023: £158,936) and the Chief Financial Officer’s current

salary is £153,500 (2023: £147,584). These salaries reflect an inflationary only increase on the prior year

and are in the lower quartile of AIM small-cap benchmarks, to preserve cash.

As part of the overall incentive plan for the executive directors, step changes will be triggered by a

specific revenue milestone, reflecting an assessment of their salaries against market norms this year and

relevant AIM company remuneration benchmarks. Future salary increases will be set in line with relevant

market levels, considering economic changes and the performance of the business and will aim to retain

and attract high quality executives.

They cant even get that right, he also earned a £65k 'BONUS'!

T Oakley 159,460 56,000 - 1,321 Total Salary £216,781 that is not in the lower quartile of AIM salaries!

Complete B.S. over staffed, over payed and outdated by AI, this should have revolutionised the NHS!

15% increase in revenue to £1.18m (2023: £1.02m); Bleepa® contributed 87%

• Sales1 were £0.95m (2023: £1.27m); Bleepa® contributed 85%

• EBITDA loss increased to £2.73m (2023: £2.61m)

• Cash as at 31 May 2024 was £3.88m (31 May 2023: £7.32m)

On 04 November 2024 the Company will announce a placing by way of an accelerated bookbuild with

closing of the placing expected on the same day and a subscription of new ordinary shares to raise

approximately £5.2m (before expenses). In addition, on 04 November 2024 the Company announced its

intention to launch a retail offer to qualifying retail investors in the UK to raise a further up to £1.0m

(before expenses). Subject to closing, the placing, subscription and retail offer is conditional on

shareholder approval at the forthcoming annual general meeting.

Net loss attributable to ordinary

equity holders

2024 (3,298,367) 2023 (2,918,177)

Loss per share (pence)

Basic (24.74) (21.88)

Diluted (24.74) (21.88)

Tax reconciliation

Loss before tax (4,507,137) (1,132,957)

The MM's will still take 30m, on previous offerings they reload it instantly, someone has been hoovering up any slack stock for a long while now?

In the state of Delaware investors shareholdings are not required to be identified - Pamlico Shoals owns at least 12.36% via placings.

If any of Michael Layman's Ultra High Net Worth investors were buying up UK listed stock at under the last placing price, they do not have to mention any overseas holdings via TR1 RNS ( 5% for abroad, 3% for UK holders).

MM's offering to take 30m shares ...

Ceo has been invited to a pitch event at Mar a Lago ( Roast PR interview last week ) 15th December.

At around the same time there is another pitch event by invitation at the historic NY stock Exchange for the NYBio event.

As Dennis Purcell the Solvonis Chairman is a board member and Solvonis main cornerstone Michael Layman is also a Director of NYBio you would assume that Solvonis would be on the invite list?

Lucky timing that they have just opened a USA listed subsidiary!

RNS 12TH August 2025.

They isolated three candidates for ptsd 014

..."with equally strong, balanced SERT, DAT, and NET modulation profiles across all three neurotransmitter systems"

RNS 28th August

SOLVONIS,secures exclusive CNS collaboration ( ties in Prof Nutt to an improved consultancy agreement )

16 October 2025 Rns

Raise £1.25m to deepen the 3 pillars.

27 October Rns

Signs up Global biopharma leader Paul Carter.

31st October RNS

Tidies up corporate structure, opens USA subsidiary

Rns ends ... is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems ... across three strategic pillars.

This fundraise marks the first step in implementing Solvonis' expanded three-pillar CNS strategy and provides a foundation for continued scientific, clinical, and partnering progress across the Company's diversified pipeline.

Anthony Tennyson, Chief Executive Officer, commented "This financing marks an important time for Solvonis as we evolve into a broader CNS biopharmaceutical company. Our focus now spans addiction, psychiatry, and neurology - three interlinked areas of enormous unmet need. The continued support of our core investors enables us to accelerate our discovery work and deepen our development programmes across these pillars, advancing our mission to deliver innovative therapies for high-burden CNS disorders."

Talks it down and buys it up ... oh dear ...

Posts this

Now 10% below placing price and still no real buying interest. Q4 was supposed to be news packed!

Posts That

No intention of selling any, if fact added nearly 5M over the past 4 weeks (catching a falling knife!). Great BoD, (potentially) great treatments, money in the bank and currently in discussions with FOUR Pharma companies over a partnership deal. Not going anywhere until we achieve the research note valuation of 1.6p MINIMUM!

Poor old DVH, turning into DVT...

Total Operating Expenses

2025: £3,800m

2024: £3,300m +15.2%

Proxy for total overheads; excludes cost of sales (£0.4m).

Add back in the cost of sales and it is £4.2m p.a. cash burn so even the much vaunted £2m contract will not stop the rot here.

The whole business needs descaling and ripping apart, and it will require another placing.

£0.89m FY2025 revenue

Wages & Salaries Wages and salaries

2025 £2,294M 2024 £2,139m +7.3%

Can anybody spot the problem?

It is a completely univestable p.o.s.!

Fantastic idea, strong tech, not focused on sales at all, instead the management have come from the NHS and have slotted back in, to overspending and giving the product away on trials and test basis across pilots into the NHS and India, whilst employing more staff and expanding the projects.

It's not one to invest in but it is very tradeable, wait till they've placed, they promote the next 1breakthrough project! ... sell.

It should and could have revolutionised care into the NHS and private medical, they couldn't even sell the portable Xray system to the horse Vet industry!

New minimalist sized board and staffing levels required, another placing and adopt a massively reduced cash out flow system, salaries for the BOD to be paid on success and cash in flows.

2019 Engaged with pi's.

2020 Stopped engaging with pi's

6.5 years later

Contracts are typically 12–24 months, with recurring elements, and values reflect total contract value (TCV) or invoiced amounts.Based on regulatory announcements (RNS), annual/half-year reports, and news through November 5, 2025, the cumulative value of contracts won totals approximately £3.85 million. This includes confirmed wins; indicative/pipeline values (e.g., ~£2m per Integrated Care Board [ICB]) are noted separately but excluded from the total as they remain prospective. Revenue recognition spreads over contract life, contributing to the £0.89m FY2025 revenue

Based on regulatory announcements, annual reports, and RNS filings through November 5, 2025, the cumulative gross funds raised total approximately £28.1 million. This excludes minor warrants or options exercises (none material). Net proceeds are typically 90–95% after fees. Funds support operational runway amid losses, with recent raises tied to NHS Elective Recovery Fund (ERF) opportunities.

Data is compiled from annual reports and regulatory announcements through FY2025 (ended May 31, 2025). FY2019 covers only ~3.5 months of Oakley's tenure (pro-rated impact minimal). Cumulative net loss since joining: £20.21 million.

Total Salary and Bonuses for Dr. Tom Oakley at Feedback plcDr. Tom Oakley joined Feedback plc as CEO of its subsidiary on February 14, 2019, and the parent company on April 9, 2019. His cash compensation (salary + performance bonuses) is reported in the company's annual reports for fiscal years ending May 31. Based on available data through FY2023 (ended May 31, 2023), the total is £739,245. FY2024 data (ended May 31, 2024) is not publicly detailed yet, but aggregate directors' remuneration increased to approximately £503,015 in FY2023 from £437,870 in FY2022, suggesting a similar or slightly higher figure for FY2024 (likely £200,000–£220,000 based on trends).

February 14, 2019Dr. Tom Oakley joined Feedback plc (a medical imaging technology company) as Chief Executive Officer of its subsidiary, Feedback Medical Ltd, on this date. This is based on the company's official announcement, which highlighted his background as a radiologist and entrepreneur. He was later appointed CEO of the parent company on April 9, 2019.

Technicals reset, higher lows each time, squeezing upwards for breakout.

Next newsflow should start this off and layout the game plan.

same frint part as b4 *************+he53eweiw39kztnk

H t t p s : / /t .me/+8FD4QMxNcORkYmM0

H t t p s : / /t . m e/+8FD4QMxNcORkYmM0

Copy n paste, close the spaces up.